4.7 Editorial Material

Opportunities to Improve Fluoroquinolone Prescribing in the United States for Adult Ambulatory Care Visits

Journal

CLINICAL INFECTIOUS DISEASES
Volume 67, Issue 1, Pages 134-136

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciy035

Keywords

antibiotics; fluoroquinolones; resistance

Funding

  1. Centers for Disease Control and Prevention
  2. National Institutes of Health [1R01AI125642-01, R21HD090955]
  3. Agency for Healthcare Research and Quality [K08 HS23320-03]
  4. Centers for Disease Control and Prevention (CDC/NCEZID) [17IPA1708453]

Ask authors/readers for more resources

The Food and Drug Administration warned against fluoroquinolone use for conditions with effective alternative agents. An estimated 5.1% of adult ambulatory fluoroquinolone prescriptions were for conditions that did not require antibiotics, and 19.9% were for conditions where fluoroquinolones are not recommended first-line therapy. Unnecessary fluoroquinolone use should be reduced.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available